Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219966 · ClinicalTrials.gov registry record · Phase 3
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
A Phase 3 study of Alcohol Use Disorder, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,100
- Enrollment target
- 20
- Study locations
NCT07219966: Recruiting Phase 3 study of Alcohol Use Disorder, sponsored by Eli Lilly and Company.
NCT07219966 is a Phase 3 study of Alcohol Use Disorder that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 1,100 participants, above the 322-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (242% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07219966, a Phase 3 study of Alcohol Use Disorder, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3537031
Study Locations (20)
Florida
- Accel Research Sites - Lakeland Clinical Research Unit - Lakeland
- K2 Medical Research - Maitland - Maitland
- K2 Medical Research ORLANDO - Maitland
- Life Arc Research Centers - Miami - Miami
- Wellness Research Center - Miami
- Life Medical Research Group Corp - Miami Gardens
- Charter Research - Orlando - Orlando
- K2 Medical Research - Tampa - Tampa
California
- UCLA Clinical & Translational Research Center (CTRC) - Los Angeles
- Artemis Institute for Clinical Research - San Diego
- UCSF Weill Institute for Neurosciences - Substance Use Disorders Clinic - Mission Bay - San Francisco
Maryland
- Maryland Treatment Centers - Mountain Manor Treatment Center - Baltimore
- Maryland Treatment Centers - Avery Road Treatment Center - Rockville
Alabama
- Parkway Medical Center - Birmingham
Arizona
- Headlands Research - Scottsdale - Scottsdale
Arkansas
- Woodland International Research Group - Little Rock
Colorado
- Mountain Mind - Denver - Denver
Illinois
- Re:Cognition Health - Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2025-10-15 |
| Est. Completion | 2028-04 |
| Phase | Phase 3 |
What NCT07219966 shows while recruiting
NCT07219966 is an interventional study that assigns participants to a tested intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, above the 322-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (242% higher).
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07219966 names 20 study sites across 10 states, led by Florida, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT07219966 about?
NCT07219966 is a clinical study titled "A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder". The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.
What is the current status of trial NCT07219966?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2025-10-15. Estimated completion is 2028-04.
What conditions does trial NCT07219966 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT07219966?
The interventions under investigation include: Placebo (DRUG), LY3537031 (DRUG).
Who is sponsoring clinical trial NCT07219966?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219966 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07219966's enrollment target sits among peer trials
1,100 5th of 184 higher than 179 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Brenipatide in Participants With Alcohol Use Disorder
RECRUITING · Phase 3
-
Emergency Department-Initiated Medications for Alcohol Use Disorder
RECRUITING · Phase 3
-
Electronic Harm Reduction Treatment for Alcohol
RECRUITING · Phase 3
-
Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action
COMPLETED · Phase 3
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI